Nucleate Podcast

Nucleate

Nucleate is the new voice for next generation biotech leaders.

  1. vor 5 Tagen

    Using Philanthropy to Drive Cures for Multiple Myeloma | Stephanie Oestreich, PhD MMRF

    (0:53) Introduction to Stephanie’s passion for science and her career transition from research to business (8:40) Key foundational business development skills  (13:06) What investors look for when evaluating early stage technology (14:37) The story behind Gleevec and its commercialization journey  (19:36) Long term planning for early career scientists  (24:39) Differences between U.S. and European ecosystems across pharma and biotech  (30:30) Introduction to the Multiple Myeloma Research Foundation  (36:23) How in vivo CAR-T and cell therapy are advancing  multiple myeloma care (42:08) Advice for entrepreneurs interested  in the Nucleate Activator program   (54:18) How can startup founders best position themselves in a competitive landscape (1:03:10) Quick fire questions

  2. 23. Juni

    Translating Science into Patient Impact with Kendra Rose

    Time Stamps: (2:37) Introduction to Kendra’s professional journey and how she found her path into science  (7:30) Understanding the consumer mindset and patient perspectives (13:05) Key parameters that shape important decisions  (17:45) Core lessons on bridging the gap between science and business  (25:30) Introduction to Bayer and Kendra’s  role as Senior Vice President of Business Development and Licensing  (29:46) Latest trends shaping healthcare research,  education, and innovation  (38:59) How to establish credibility as an entrepreneur in a competitive market (41:28) Inside the Bayer Co.Lab incubator ecosystem and the support it offers (50:37) Tips for early-career scientists interested in making a pivot from the lab to business (57:09) Do you really need a Ph.D. to break into pharma? (1:00:01) Quick fire questions

  3. 4. Juni

    Leading Mission-Driven Biotechs | Jodie Morrison, CEO of Q32 Bio

    Time Stamps 01:42: Jodie’s early interest in science and the defining moment   03:31: Starting from the bottom in clinical research shaped her leadership style as a CEO 08:32: How she joined Q32 Bio and then took them public 10:11: Jodie’s inspiration to get involved with challenging companies 11:42: The emotional reward of biotech: the long hours are worthwhile to save lives   13:46: Navigating challenging situations 15:10: Q32 Bio's focus on autoimmune disorders 19:59: The origins of the CEO Forum 27:54: The "lonely" nature of being a CEO and the importance of community 30:54: Philosophy on female leadership: “lift while we climb” 34:54: How AI is involved in biotech 43:24: Navigating challenging capital markets: focus on “killer experiments” that investors want 46:47: Balancing "ethical obligation" to employees with their "fiduciary responsibility" to investors 49:56: How layoffs are “heartbreaking” but necessary to preserve capital for future drug development 56:30: The future of biotech is "cautious optimism" but needed 1:00:06: Initiatives among leaders to heal the misconception of science 01:05:01: Rapid Fire questions

  4. 24. März

    From Genomics to Deal-Making: How Science Becomes a Company | Laurence Reid, Biotech Entrepreneur

    Time Stamps [00:00] Laurence explains biotech to a five-year-old  [01:55] Early life in the UK and first steps toward biotech  [02:47] How The Double Helix and Celltech shaped his path  [07:15] Moving from bench science to Cell and a wider view of research  [13:04] Learning business development at Millennium [15:30] Why relationships matter in biotech deals  [17:43] How Millennium changed from platform company to drug developer  [28:01] Joining Alnylam and building around RNAi  [39:19] Becoming a CEO at Warp Drive Bio  [44:36] Novel antibiotics, molecular glues, and the RevMed merger [52:07] What founders should know about building to make a lasting impact [54:50] Joining Decibel during restructuring and COVID  [58:55] Rebuilding culture and sharpening strategy  [1:09:49] Why Decibel focused on gene therapy for the inner ear [1:25:05] Advice for founders raising money in a hard market

  5. 10. März

    Negotiating Intellectual Property, Staying Focused, and Making the Most of Mentors with Michal Preminger, Board Member at MassBio

    Time Stamps (0:55) Introduction to Michal’s background and her professional journey  (7:58) How Michal leveraged tech skills to break into computational biology  (13:15) Her experience at Compugen working on early AI-enabled drug discovery   (19:52) Challenges startup founders face and strategies to overcome them (25:19) Michal’s personal experience as a founder at Anima Biotech (32:52) Resources available at academic institutions to support startups  (40:15) How to successfully negotiate as a scientific founder (46:51) Michal’s role at Johnson & Johnson (53:13) Introduction to MassBio and their purpose (58:35) Advice on networking and how to form meaningful partnerships

  6. 24. Feb.

    How Turbine Accelerates Drug Discovery with AI Simulation | Szabi Nagy, CEO and Co-Founder of Turbine

    Time Stamps 1:37 Introduction to Szabi’s journey from economics to healthcare  3:23 Szabi’s early startup experience at Tresorit  5:27 Key takeaways from his first venture 11:46 What led Szabi to pivot into healthcare and how he managed that transition 14:37 Introduction to Turbine 17:10 Example of running large-scale experiments in collaboration with Merck  19:17 Explanation of the main phases of application of the model  22:32 What fundamental tenets were used to build Turbine’s model  29:16 How to form successful partnerships 38:53 Szabi’s experience with raising funds in a tight capital market  40:00 Advice for founders navigating this challenging market 49:20 How to find the right mentor and form a meaningful connection  51:07 Final words of wisdom

  7. 10. Feb.

    The Science of Stem Cells and Social Impact: Inside Ovelle with Merrick Smela and Travis Potter

    Time Stamps 1:58 Merrick Smela's Early Influence 03:36 Ovelle's Founding:  Travis Potter and Merrick Smela 05:07 Travis Potter's Motivation After Facing Fertility Struggles 06:44 Underfunding of IVG 07:48 Finance/Biotech Commonalities 09:15 Scientific Co-founder Role: Merrick Smela 09:56 Using Statistics in Design 12:25 Definition of IVG 12:54 Ovelle's Mission to Revolutionize Infertility Treatment 13:33 IVG vs. IVF 15:49 Ovelle's Unique Scientific Approach 16:39 Direct Activation vs. Natural Signaling:  18:17 Meiosis Paper Innovation: Identifying Regulatory Factors that can Activate Meiosis from Stem Cells 21:23 Team Building: Finding Dedicated Scientists 24:20 Culture Difference (Meaning vs. Money) 28:35 IVG Process Overview:  29:36 IVM is Achieved in Humans:  30:35 Quality Control and Safety of Eggs 32:35 Prioritization using Critical Path Analysis: 35:02 Investor Funding for IVG as a New Fertility Approach 41:21 Rapid Fire Questions

  8. 27. Jan.

    Inside TechBio Investing | Claire Smith, Partner at Springtide VC

    In this episode of the podcast we sit down with Claire Smith, Partner at SpringTide. She reflects on her journey from a biological engineering student at MIT to her current role in venture capital, and the key lessons she’s learned along the way. Claire explains SpringTide’s investment scope, introduces companies from her portfolio, and shares what drives her investment decisions. The conversation also explores the current landscape of TechBio and AI, including how to distinguish genuine innovation from hype, how pharma is realistically adopting AI, and differences in East Coast and West Coast perspectives on the technology.  Claire provides guidance for early-stage founders navigating today’s ever-changing environment. She discusses the importance of planning realistic timelines, how and when to launch a company, and what qualities investors are looking for. She advises on what makes a great pitch, arguing that the goal of the initial meeting is not to secure funding, but to earn a second conversation. Trust is built through preparation, authenticity, and intellectual honesty, never by faking it in biotech.  Books mentioned:  The Pyramid Principle by Barbara MintoWhy Genius Failed: The Rise and Fall of Long-Term Capital Management by Roger LowensteinTime Stamps: 0:01:20 Introduction to Claire’s  journey from MIT biological engineering to SpringTide 0:05:44 There’s “no overnight successes” in biotech 0:06:47 Claire’s experience as a start up operator at Crestovo and the key lessons she learned 0:09:35  Explanation of the investment  scope of Springtide  0:12:31 How Claire assesses risk when building an investment portfolio  0:14:47 Things to consider when evaluating technical founders 0:15:55 Introduction to Paterna Biosciences and their impact within the fertility space   0:19:27 Platforms vs assets in tough capital markets and why Springtide has a countercyclical platform focus 0:22:50 Meaning of “look boring today, but will be infrastructure tomorrow” 0:24:24 Advancements in Palantir‑style business models for pharma 0:28:42 What does the term “TechBio” means to Claire 0:30:39 How the pharma industry is currently leveraging AI  0:33:55 Markers of AI success to keep an eye out for 0:35:29 How to identify companies that are driving genuine AI innovation 0:37:50 Example of Niche Bio and how they’re generating data for machine learning 0:39:22 Differences in opinions between East Coast and West Coast investors on AI 0:42:16 Advice for companies navigating the current capital market 0:44:16 Why proactive buffer planning is critical when setting a timeline 0:45:36 Advice for early stage founders on how and when to launch their company  0:50:59 What sets a great pitch apart  0:55:00 Explanation of the Pyramid Principle by Barbara Minto 0:55:44 3 main points about SpringTide as an investment firm 0:58:28 Importance of forming authentic connections but don’t “fake it ‘til you make it”  1:01:22 Quick-fire questions

Alle anzeigen (47)

Info

Nucleate is the new voice for next generation biotech leaders.

Informationen

  • Erstellt von
    Nucleate
  • Jahre aktiv
    2023 - 2026
  • Folgen
    47
  • Bewertung
    Unbedenklich
  • Copyright
    © 2024 Nucleate Podcast
  • Sendungswebsite
    Nucleate Podcast

Das gefällt dir vielleicht auch